All news

CorMedix to buy substantially all of Heron Therapeutics' assets for about $222.6 million upfront

GlobeNewswire · · AI-summarised by FinFlash

CorMedix Therapeutics agreed to acquire substantially all assets of Heron Therapeutics for

So What?

Heron shareholders face an asset sale rather than a premium takeover, so watch the vote and HRTX trading versus deal value; CorMedix adds leverage via a Pharmakon loan, a factor for CRMD's balance-sheet risk.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.